« EMA reconsiders and gives its positive opinion for the approval of ixazomib Addition of daratumumab to bortezomib and dexamethasone in patients with… »
SURVEY: Reasonable agreements between pharmaceutical companies and patient advocates Published October 6, 2016 MPE, in collaboration with other patient organisations, is conducting a project to analyse legal agreements of pharmaceutical companies with patient advocates. The project will make suggestions for simpler, more understandable agreements that would sufficiently reflect and protect the interests of both parties. Recent news» Daratumumab approved for first line treatment in Israel» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. I accept the Privacy Policy
Leave a Reply